Anti-Rheumatic Drugs - Namibia | Statista Market Forecast

The projected revenue for the Anti-Rheumatic Drugs market in Namibia is expected to reach US$2.28m in 2024.
Looking ahead, the market is forecasted to grow at an annual growth rate of 0.22% (CAGR 2024-2029), resulting in a market volume of US$2.31m by 2029.
It is worth noting that in global comparison, United States is anticipated to generate the highest revenue in this market, with an estimated value of US$34.70bn in 2024.
Namibia's market for anti-rheumatic drugs is experiencing a steady increase in demand due to the high prevalence of rheumatic diseases in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

Namibia, a country in southern Africa, has been experiencing a steady growth in the Anti-Rheumatic Drugs market.

Customer preferences: Patients suffering from rheumatoid arthritis in Namibia prefer Anti-Rheumatic Drugs due to their effectiveness in reducing inflammation and pain. These drugs are also preferred over other treatment options due to their ease of use and affordability.

Trends in the market: The Anti-Rheumatic Drugs market in Namibia has been growing steadily due to an increase in the prevalence of rheumatoid arthritis in the country. This growth is also attributed to the increase in demand for biologic drugs. The market has seen a shift towards the use of biologic drugs due to their higher efficacy and fewer side effects compared to traditional disease-modifying antirheumatic drugs (DMARDs).

Local special circumstances: Namibia has a high prevalence of rheumatoid arthritis, which has been attributed to the genetic makeup of the population. The country also has a high incidence of HIV, which has been linked to an increased risk of rheumatoid arthritis. The government of Namibia has been working towards improving access to healthcare services in the country, which has led to an increase in the diagnosis and treatment of rheumatoid arthritis.

Underlying macroeconomic factors: The Namibian economy has been growing steadily over the years, which has led to an increase in the disposable income of the population. This increase in disposable income has led to an increase in the demand for healthcare services, including the Anti-Rheumatic Drugs market. The government of Namibia has also been investing in the healthcare sector, which has led to an increase in the availability of healthcare services in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.